TABLE 1.
Characteristics of included studies.
| Study | Location | No. D+R- patients | CMV disease, n | Graft loss, n | Death, n | Acute rejection, n | CMV prevention strategy | CMV disease definition(s) used |
|---|---|---|---|---|---|---|---|---|
| UP studies | ||||||||
| Humar et al (2010) | Multicenter | 155 | 25 | 3 | 0 | 17 | UP | Humar et al (2006) |
| Leone et al (2010) | France | 67 | 15 | NR | NR | NR | UP | Humar et al (2006) |
| Abate et al (2010) | Italy | 13 | 1 | 0 | 0 | 1 | UP | No definition listed |
| Boudreault et al (2011) | USA | 34 | 11 | 0 | 1 | 12 | UP | Humar et al (2006) |
| Abate et al (2013) | Italy | 20 | 1 | NR | 0 | NR | UP | Custom definition |
| Manuel et al (2013) | Switzerland | 28 | 7 | 3 | 1 | NR | UP | Humar et al (2006) |
| Posadas Salas et al (2013) | USA | 44 | 2 | 4 | 1 | 0 | UP | Custom definition |
| Gabardi et al (2015) | USA | 107 | 26 | 3 | 3 | 14 | UP | Custom definition |
| Stevens et al (2015) | USA | 45 | 5 | 1 | 1 | 4 | UP | Humar et al (2006) |
| Perez-Jacoiste Asin et al (2016) | Spain | 8 | 4 | 0 | 0 | 0 | UP | Humar et al (2006) |
| Puttarajappa et al (2016) | USA | 42 | 14 | 2 | 2 | 17 | UP | No definition listed |
| Fleming et al (2017) | USA | 17 | 3 | NR | NR | NR | UP | Custom definition |
| Freedman et al (2019) | USA | 138 | 35 | 4 | 4 | 16 | UP | Ramanan et al (2013) and Kotton et al (2018) |
| Perez-Flores et al (2019) | Spain | 23 | 8 | 0 | 0 | 6 | UP | Ljungman et al (2017) |
| Andreani et al (2020) | France | 12 | 4 | NR | NR | 0 | UP | Humar et al (2006) |
| Hellemans et al (2021) | Belgium | 40 | 5 | 0 | 0 | 2 | UP | Razonable and Blumberg (2015) |
| Nowak et al (2021) | Germany | 56 | 10 | NR | 1 | 18 | UP | Ljungman et al (2017) |
| Raiha et al (2021) | Finland | 136/481a | 52 | 14 | 9 | 56 | UP | Razonable et al (2019) and Ljungman et al (2017) |
| Aboujaoude et al (2021) | Lebanon | 8 | 2 | 0 | 0 | NR | UP | No definition listed |
| PET studies | ||||||||
| HT PET studies | ||||||||
| Couzi et al (2012) | France | 80 | 21 | 8 | 0 | 16 | HT PET | Humar et al (2006) |
| Atabani et al (2012) | UK | 40 | 15 | NR | NR | 4 | HT PET | Ljungman et al (2002) and Kotton et al (2010) |
| LT PET studies | ||||||||
| van der Beek et al (2010) | The Netherlands | 35 | 1 | 1 | 0 | NR | LT PET | Ljungman et al (2002) |
| Martin-Gandul et al (2014) | Spain | 23 | 2 | 0 | 0 | 3 | LT PET | Ljungman et al (2002); de La Torre Cisneros et al (2011); Kotton et al (2013) |
| Cantisan et al (2016) | Spain | 25 | 3 | NR | 0 | NR | LT PET | de la Torre-Cisneros et al (2011) |
| Lumley et al (2019) | UK | 31 | 1 | 0 | 0 | NR | LT PET | Ljungman et al (2017) |
aRaiha et al (2021) examined two cohorts: a cohort of 481 D+R- KTRs in which clinical outcomes (graft loss, acute rejection, and mortality) were studied, and a subcohort of 136 patients in which CMV disease incidence was collected.
CMV, cytomegalovirus; D+R-, donor seropositive recipient seronegative; HT, high threshold; KTR, kidney transplant recipient; LT, low threshold; NR, not reported; PET, preemptive therapy; UP, universal prophylaxis.